Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dengue Disease Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 27, 2026, 8:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS

NCT01702272
View directory record Official record
Conditions
Dengue
Interventions
Procleix Dengue Virus Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
Not listed
Enrollment
150,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

NCT00919178
View directory record Official record
Conditions
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions
DEN4 Vaccine Candidate, DEN4 Vaccine Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

NCT01502735
View directory record Official record
Conditions
Dengue Fever
Interventions
DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain

NCT02372175
View directory record Official record
Conditions
Dengue
Interventions
Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 27, 2026, 8:22 AM EDT
Recruiting Phase 2Phase 3 Interventional

Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

NCT07016321
View directory record Official record
Conditions
Dengue
Interventions
Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

NCT02392325
View directory record Official record
Conditions
Dengue
Interventions
rDEN1Δ30, Placebo, rDEN2Δ30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

NCT03746015
View directory record Official record
Conditions
Dengue Fever
Interventions
TDV
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Peoria, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

NCT00118924
View directory record Official record
Conditions
Tick-Borne Encephalitis
Interventions
LGT(TP21)/DEN4, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2008 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

NCT01782300
View directory record Official record
Conditions
Dengue
Interventions
TV003 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01506570
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

NCT05048875
View directory record Official record
Conditions
Dengue
Interventions
Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 27, 2026, 8:22 AM EDT
Enrolling by invitation No phase listed Observational

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07520279
View directory record Official record
Conditions
Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions
Xpert Tropical Fever test
Diagnostic Test
Lead sponsor
Cepheid
Industry
Eligibility
14 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

NCT03771963
View directory record Official record
Conditions
Dengue Fever
Interventions
Tetravalent Dengue Vaccine (TDV)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Anaheim, California • Hutchinson, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

NCT00712803
View directory record Official record
Conditions
Dengue
Interventions
rDEN3-3'D4delta30
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

NCT02061358
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

NCT00617344
View directory record Official record
Conditions
Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
Interventions
Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
5
States / cities
Hoover, Alabama • San Diego, California • Vallejo, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577
View directory record Official record
Conditions
Dengue
Interventions
Live attenuated tetravalent dengue vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

NCT00270699
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN4delta30-200,201, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147
View directory record Official record
Conditions
Dengue
Interventions
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 27, 2026, 8:22 AM EDT
Completed No phase listed Observational

Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

NCT02794181
View directory record Official record
Conditions
Zika Virus, Dengue Virus, Chikungunya Virus Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 27, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

NCT01084291
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for DEN1, Placebo injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 27, 2026, 8:22 AM EDT